Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 13/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30892954 | 1.00 | SMO (0.37) | SMONR1H4P2RX7HSD11B1KIT | |
| SCHEMBL27213684 | 0.88 | NR1H4 (0.40) | NR1H4P2RX7HSD11B1GABRA5 | |
| SCHEMBL30849280 | 0.85 | NR1H4 (0.34) | NR1H4P2RX7HSD11B1 | |
| SCHEMBL27394436 | 0.80 | P2RX7 (0.39) | NR1H4P2RX7HSD11B1 | |
| SCHEMBL30892906 | 0.80 | P2RX7 (0.39) | NR1H4P2RX7HSD11B1 | |
| SCHEMBL30849221 | 0.78 | P2RX7 (0.39) | NR1H4P2RX7HSD11B1 | |
| SCHEMBL27392402 | 0.78 | P2RX7 (0.39) | NR1H4P2RX7HSD11B1 | |
| SCHEMBL27213713 | 0.78 | P2RX7 (0.39) | NR1H4P2RX7HSD11B1 | |
| SCHEMBL27213745 | 0.78 | HSD11B1 (0.37) | NR1H4HSD11B1 | |
| SCHEMBL27392398 | 0.78 | HSD11B1 (0.37) | NR1H4HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | SMO 2999/4885NR1H4 94/4885P2RX7 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.